Test Announcement: Combined Influenza and SARS-CoV-2 Testing

Effective today, January 27, 2021, PathGroup is pleased to announce a new multiplex nucleic acid amplification molecular diagnostic test (NAAT) for Influenza A/B & SARS-CoV-2 on the Roche cobas^® instrument. This real time RT-PCR based assay is intended for the simultaneous qualitative detection and differentiation of Influenza A virus, Influenza B virus, and/or SARS-CoV-2 RNA from appropriately collected specimens from individuals suspected of associated respiratory viral infection. This test has been issued an Emergency Use Authorization (EUA) by the FDA.

Click here to learn more.